Greedy pigs!!!!

Quote
Anonymous said:
Hey Melvin, another poster here. Gilead has a PR nightmare brewing due to this price gouging (even if it is less expensive than the cost of treating a patient with decompensated disease). Your company, which hired mostly inexperienced GI reps with no HCV experience (because you couldn't afford to hire experienced HCV reps like me who happily turned down the position) who are stumbling around in offices trying to figure out how to handle the negative press (especially in the community practices) and are using the company line "don't shoot the messenger", is trying to recoup the $11 billion this year because once you have real competition, docs will be happy to try other drugs. The days of the Schering and then Roche/Genentech market ownership will be over once you have 2 other competitors. Providers have already said so, that they won't put all of their patients in your basket. Considering your payer team sucks (another reason I walked away because I did my homework) means that BMS and Abbvie will challenge aggressively for preferred status and take lower reimbursement. John Martin may be America's newest billionaire but his legacy will reflect how greed taints the public perception of corporate America. Patients are not commodities but that is how your employer views them.
Click to expand...

Please you wanted to be here so bad that you wrote a page long message on CP, walked away? Turned down sounds more like it. I love when reps think they have a PHD, you're a rep. Please stop blabbering on here, it's clogging up the good stuff.
 






Anonymous said:
Please you wanted to be here so bad that you wrote a page long message on CP, walked away? Turned down sounds more like it. I love when reps think they have a PHD, you're a rep. Please stop blabbering on here, it's clogging up the good stuff.
Click to expand...

My Fellow Pharma Friend (used loosely). I did turn it down last May and the woman who got the position is making a fool of herself. I'm watching what has happened since then from the sidelines and am thanking myself that I made the decision to turn it down everyday. No need for a PhD to figure out the reality of what working there would have been like, especially with the likes of the manager who was a tool. No blabbering dude, just stating my case. If this happens to be DC from NYC who used to work for genentech, go "f" yourself you loser.
 


















Anonymous said:
All over the headlines for selling a 6 week drug for 84,000. You should be ashamed of yourselves! Pathetic!!!!
Click to expand...
Why don't you look at the price of all of the specialty drugs and then research why they are so expensive. Look at how many more people can be treated and that is the only reason the price is an issue. There aren't any specialty drugs in HCV that will be much less in the near future. The years of research it takes to get a drug to market and make sure people don't sue for something not caught in trials is why the greed of America has driven the prices of drugs up. If people knew there are risks in taking new drugs to eliminate a disease it would make access change and prices change. Until that happens, Amercia will micromanage and drive costs of drugs and ruin access. The greed isn't in pharma, who paid for the 10 years of research and 3 phases of trials to get the drugs to market? You get what you pay for. If you want something cheap go to the vitamin store and buy a hoax and guess what it won't work.
 






Hey Pigs: Your reckoning is coming NOW!!! More than a dozen European countries are joining forces to negotiate a lower price for the Sovaldi treatment sold by Gilead Sciences GILD -0.30%. And yesterday, two U.S. senators, one of whom heads the Senate Finance Committee, yesterday wrote the drug maker to ask for detailed financial information about the $11 billion deal in which Gilead acquired the drug, R&D costs and subsequent pricing forecasts.
 






Anonymous said:
Hey Pigs: Your reckoning is coming NOW!!! More than a dozen European countries are joining forces to negotiate a lower price for the Sovaldi treatment sold by Gilead Sciences GILD -0.30%. And yesterday, two U.S. senators, one of whom heads the Senate Finance Committee, yesterday wrote the drug maker to ask for detailed financial information about the $11 billion deal in which Gilead acquired the drug, R&D costs and subsequent pricing forecasts.
Click to expand...

I'm going to think of your jealous post tonight when I light a cigar with a $20 bill celebrating this weeks new record high stock price.
 






Anonymous said:
Hey Pigs: Your reckoning is coming NOW!!! More than a dozen European countries are joining forces to negotiate a lower price for the Sovaldi treatment sold by Gilead Sciences GILD -0.30%. And yesterday, two U.S. senators, one of whom heads the Senate Finance Committee, yesterday wrote the drug maker to ask for detailed financial information about the $11 billion deal in which Gilead acquired the drug, R&D costs and subsequent pricing forecasts.
Click to expand...

Here's what Gilead will say:

Incivek + Pegasys + RBV for 48 weeks = $107,000 (not including growth factors) and maybe a 60% svr
Victrelis + Pegintron + RBV for 48 weeks = $96,000 (not including growth factors) and maybe a 60% svr

SOVALDI + Pegasys + RBV for 12 weeks = $95,000 and more than 90% svr

That's facts my friends. I anticipate those Senators getting down on their knees and bowing at that point.
 






Anonymous said:
Here's what Gilead will say:

Incivek + Pegasys + RBV for 48 weeks = $107,000 (not including growth factors) and maybe a 60% svr
Victrelis + Pegintron + RBV for 48 weeks = $96,000 (not including growth factors) and maybe a 60% svr

SOVALDI + Pegasys + RBV for 12 weeks = $95,000 and more than 90% svr

That's facts my friends. I anticipate those Senators getting down on their knees and bowing at that point.
Click to expand...

Fuck yes baby!
 






























Anonymous said:
Abbvie is going to kick your greedy big butts back to California! Oh are you the Burger King?!? Ha! Ha!
Click to expand...

Again, everyone tries to dethrone the king. It's kind of strange that we don't go post on the Abbive or Merck board, probably because winners don't do that. Keep it coming, it just reiterates our dominance.
 


















SHAME ON YOU!! Your management will be crapping in their pants in front of Congress!! Will the cost of new hepatitis C treatments bust state budgets?

A new analysis suggests many states may, in fact, be overwhelmed as they attempt to pay for the Solvaldi medication sold by Gilead Sciences GILD +4.84%, which costs $84,000 for each patient, and several forthcoming treatments that may be priced at a similar level.

More than 750,000 Americans with chronic hepatitis C receive health care coverage through Medicaid or the prison system. And in its analysis, Express Scripts ESRX +0.61%, the nation’s largest pharmacy benefits manager, consequently projects that states will collectively spend more than $55.2 billion to provide Sovaldi to all comers.
 






And what Express Scripts and others AREN'T saying is how much it saves the states Medicaid/Medicare systems by potentially CURING HEP C. Before you start throwing out the "Shame On You" crap do a little research into the overall cost of the disease to the state systems and then pop off.
 






There have been patients "warehoused" for years waiting on this (and all the other companies) cure for Hep C. This therapy IS more expensive when broken down to the "per day" cost but it is much less expensive with twice the efficacy and a lower side effect profile than previous therapies. If you had HepC you would want to only take 12 weeks of therapy (a pill vs infusion) with an excellent chance of curing it! State Medicaids and Commercial Payers were warned that this was coming. Everyone complains that pharma is into life cycle management and just extends patents by making little changes to their formulations to stave off a generic but when someone comes out with a curative, innovative drug everyone complains about the cost. Can't really have it both ways.
 






Anonymous said:
There have been patients "warehoused" for years waiting on this (and all the other companies) cure for Hep C. This therapy IS more expensive when broken down to the "per day" cost but it is much less expensive with twice the efficacy and a lower side effect profile than previous therapies. If you had HepC you would want to only take 12 weeks of therapy (a pill vs infusion) with an excellent chance of curing it! State Medicaids and Commercial Payers were warned that this was coming. Everyone complains that pharma is into life cycle management and just extends patents by making little changes to their formulations to stave off a generic but when someone comes out with a curative, innovative drug everyone complains about the cost. Can't really have it both ways.
Click to expand...

Correction douche, interferon is not an infusion......turd
 






Top Bottom
Back
Quote